Published in Immunobiology on December 01, 2001
Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood (2005) 1.52
An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. Nat Immunol (2010) 1.39
Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med (2010) 1.18
The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells. J Virol (2007) 1.13
A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol (2009) 0.99
The migration of T cells in response to influenza virus is altered in neonatal mice. J Immunol (2010) 0.98
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. J Leukoc Biol (2012) 0.95
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92
Contributions of E1A to mouse adenovirus type 1 pathogenesis following intranasal inoculation. Virology (2006) 0.88
Mannose-binding lectin contributes to deleterious inflammatory response in pandemic H1N1 and avian H9N2 infection. J Infect Dis (2011) 0.88
The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infect Dis (2007) 0.84
Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunol (2013) 0.83
TLR ligands induce antiviral responses in chicken macrophages. PLoS One (2014) 0.82
Modulation of RANTES expression by HCV core protein in liver derived cell lines. BMC Gastroenterol (2007) 0.80
A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells. PLoS One (2015) 0.79
Transcription factor regulation and cytokine expression following in vitro infection of primary chicken cell culture with low pathogenic avian influenza virus. Virol J (2013) 0.75
1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice. Inflammation (2016) 0.75
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol (1982) 3.24
Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol (1988) 2.58
Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry (1973) 2.04
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
Programmed cell death (apoptosis) in human monocytes infected by influenza A virus. Immunobiology (1994) 1.98
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol (2000) 1.81
The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn (2000) 1.74
A physiological profile of tennis match play. Med Sci Sports Exerc (2001) 1.68
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol (2011) 1.66
Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation (1997) 1.64
Respiratory comfort of automatic tube compensation and inspiratory pressure support in conscious humans. Intensive Care Med (1997) 1.56
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol (2012) 1.55
Potentiation of lymphokine-induced macrophage activation by tumor necrosis factor-alpha. J Immunol (1988) 1.53
Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running. Clin Immunol Immunopathol (1992) 1.51
Kinetics of the transformation of Gram-negative rods to spheroplasts and ghosts by serum. J Immunol (1966) 1.51
Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response. J Leukoc Biol (1997) 1.51
Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol (2002) 1.42
Influenza A virus infection of macrophages. Enhanced tumor necrosis factor-alpha (TNF-alpha) gene expression and lipopolysaccharide-triggered TNF-alpha release. J Immunol (1991) 1.39
Role of macrophage cytokines in influenza A virus infections. Immunobiology (1993) 1.39
Tumor necrosis factor-alpha production of influenza A virus-infected macrophages and potentiating effect of lipopolysaccharides. J Immunol (1990) 1.36
Interleukin 1 and the glomerular mesangium. I. Purification and characterization of a mesangial cell-derived autogrowth factor. J Immunol (1986) 1.34
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33
Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol (1996) 1.31
Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages. J Leukoc Biol (2001) 1.30
Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol (1987) 1.30
Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL-1 beta, and IL-6 in human monocytes. J Immunol (1992) 1.25
Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol (1984) 1.24
Prostaglandin synthesis in spleen cell cultures of mice injected with Corynebacterium parvum. Cell Immunol (1978) 1.20
Isolated cysticercosis of the breast masquerading as a breast tumour: report of a case and review of literature. Ann Trop Med Parasitol (2011) 1.20
Behavioral treatment parameters with primary dysmenorrhea. J Behav Med (1978) 1.19
Characterization of blood mononuclear cells of rheumatoid arthritis patients. I. Depressed lymphocyte proliferation and enhanced prostanoid release from monocytes. Clin Immunol Immunopathol (1982) 1.18
The effects of phagocytosis, dextran sulfate, and cell damage on PGE1 sensitivity and PGE1 production of macrophages. J Immunol (1978) 1.17
Selective induction of monocyte and not neutrophil-attracting chemokines after influenza A virus infection. J Exp Med (1996) 1.17
Demonstration of direct glycosylation of nondegradable glucosylceramide analogs in cultured cells. J Biol Chem (1995) 1.16
Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-alpha (TNF alpha) gene expression. Res Virol (1997) 1.15
Macrophage activation by granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2. J Immunol (1989) 1.13
Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes. J Biol Chem (1995) 1.13
Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol (1986) 1.13
Differential mononuclear leukocyte attracting chemokine production after stimulation with active and inactivated influenza A virus. Cell Immunol (1998) 1.11
MIF expression in the rat brain: implications for neuronal function. Mol Med (1998) 1.10
Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict (1994) 1.10
Validation of a field test for the non-invasive determination of badminton specific aerobic performance. Br J Sports Med (2003) 1.09
Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun (1999) 1.07
Chemokines and serpentines: the molecular biology of chemokine receptors. J Leukoc Biol (1993) 1.07
Macrophage-activating factors from different T cell clones induce distinct macrophage functions. J Immunol (1983) 1.06
Release of cyclic AMP from macrophages by stimulation with prostaglandins. J Immunol (1975) 1.06
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol (2013) 1.05
Enhancement of glomerular mesangial cell neutral proteinase secretion by macrophages: role of interleukin 1. J Immunol (1986) 1.04
Control of prostanoid synthesis: role of reincorporation of released precursor fatty acids. Prostaglandins (1986) 1.03
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant (2006) 1.03
Drugs which disrupt microtubules do not inhibit the initiation of lymphocyte activation. Nature (1977) 1.01
Lysozyme and serum bactericidal action. Nature (1966) 1.01
Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene. J Immunol (1994) 1.01
Phenotype, intestinal morphology, and survival of homozygous and heterozygous endothelin B receptor--deficient (spotting lethal) rats. J Pediatr Surg (2000) 1.00
Differential effectiveness of electromyograph feedback, verbal relaxation instructions, and medication placebo with tension headaches. J Consult Clin Psychol (1975) 0.98
Immune-interferon (IFN-gamma), macrophage-activating factors (MAFs), and colony-stimulating factors (CSFs) secreted by T cell clones in limiting dilution microcultures, long-term cultures, and by T cell hybridomas. Immunol Rev (1983) 0.97
Systemic macrophage stimulation in rats with silicosis: enhanced release of tumor necrosis factor-alpha from alveolar and peritoneal macrophages. Am J Respir Cell Mol Biol (1991) 0.97
Verification of the heart rate threshold. Eur J Appl Physiol Occup Physiol (1995) 0.95
Characterization of a high molecular weight tumor necrosis factor-alpha mRNA in influenza A virus-infected macrophages. J Immunol (1994) 0.95
Induction of prostaglandin E release from macrophages by colchicine. J Immunol (1980) 0.95
Membrane perturbation and stimulation of arachidonic acid metabolism. Mol Immunol (1982) 0.95
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer (2013) 0.94
Activation of macrophages by lymphokines from T-cell clones: evidence for different macrophage-activating factors. Mol Immunol (1984) 0.94
Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res (1992) 0.93
Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. J Neurol Sci (1998) 0.93
Enhancement of the PGE1 response of macrophages by concanavalin A and colchicine. J Immunol (1977) 0.93
Differential desensitization of lipopolysaccharide-inducible chemokine gene expression in human monocytes and macrophages. Eur J Immunol (2000) 0.93
Changes in brain metabolism after ECT-positron emission tomography in the assessment of changes in glucose metabolism subsequent to electroconvulsive therapy--lessons, limitations and future applications. J Affect Disord (2007) 0.92
Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus. Enhancement of virus replication, cytokine release, and cytotoxicity. J Immunol (1993) 0.92
Activation of glomerular mesangial cells by gram-negative bacterial cell wall components. Am J Pathol (1988) 0.92
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer (2010) 0.91